New research presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition offers a glimmer of hope for patients battling blood cancers.Studies highlight significant advancements in prevention, early intervention, and treatment strategies across the spectrum of these diseases.
“It’s very encouraging to see advances being made across the continuum of care for blood cancers,” said Dr. Surbhi Sidana, an associate professor of medicine at Stanford University in California, who moderated the briefing Diagnosing and Treating Blood Cancers and “Almost” Cancers. “These studies focus on improving our understanding of environmental exposures that can increase cancer risk, determining whether early intervention can improve outcomes for patients with a high-risk precancerous condition, identifying promising new treatment approaches for patients for whom existing options fall short, and shedding light on the ways in which socioeconomic factors may limit patients’ access to potentially life-saving treatment.”
One groundbreaking study demonstrated the effectiveness of the drug daratumumab in significantly reducing the risk of disease progression in patients with high-risk smoldering multiple myeloma. “Patients at high risk for developing multiple myeloma who received the drug daratumumab for up to three years saw a 51% reduction in their risk of disease progression compared with similar patients who were actively monitored but not treated,” the study revealed.
Further advancements were observed in the treatment of chronic lymphocytic leukemia (CLL), the most common form of leukemia in adults in the United States. A combination regimen of two oral drugs proved highly effective in extending the time until disease worsening and minimizing adverse effects compared to standard treatment. Additionally, early results from an ongoing trial showed promising responses to epcoritamab, a biologic agent, in patients with recurring CLL who had previously undergone at least two treatments.
The research also delved into the environmental factors contributing to blood cancer risk.A study focusing on first responders who worked at the World Trade Center site following the September 11, 2001, attacks found a threefold increase in genetic changes associated with an elevated risk of blood cancer compared to non-exposed first responders or the general public. These genetic changes were also linked to a fivefold increased risk of leukemia.
Highlighting the impact of socioeconomic disparities on healthcare access, another study revealed that patients with acute myeloid leukemia living in disadvantaged neighborhoods were less likely to receive potentially curative stem cell transplants and more likely to die without receiving one. These findings underscore the urgent need to address systemic barriers to equitable cancer care.
These groundbreaking studies presented at the ASH Annual Meeting offer a beacon of hope for patients and their families, paving the way for more effective prevention, early detection, and treatment strategies in the fight against blood cancers.
A groundbreaking new study offers hope for patients with high-risk smoldering multiple myeloma, a precancerous condition that often progresses to active cancer.The research,published in the prestigious New England Journal of Medicine,found that treatment with the drug daratumumab significantly delayed or prevented the progression to active multiple myeloma compared to active monitoring.
“Compared with active monitoring, single-agent treatment with daratumumab had an acceptable safety profile and showed a clinically meaningful benefit in preventing or delaying progression to active multiple myeloma in high-risk patients,” said principal investigator Dr.Meletios A. Dimopoulos, professor and chairman of the department of clinical therapeutics at the National and Kapodistrian University of Athens School of Medicine. “These results represent a new option for high-risk patients and their physicians to consider when weighing the pros and cons of treatment versus active monitoring.”
the AQUILA study, a randomized phase III clinical trial conducted across 24 countries, involved 390 patients diagnosed with high-risk smoldering multiple myeloma.This condition carries a greater than 50% risk of developing into active cancer within two years. Currently, active monitoring, where patients are closely observed for signs of progression, is the standard of care, but the decision to treat or monitor remains a point of debate among hematologists.
Participants, with a median age of 64 and 48% being male, were randomly assigned to receive either subcutaneous daratumumab every 28 days or active monitoring for up to 36 months, or until their condition progressed to multiple myeloma.
The study’s primary goal was to determine the time elapsed between treatment randomization and a multiple myeloma diagnosis. An independent review committee,using internationally accepted diagnostic criteria,assessed disease progression. Secondary endpoints included overall response rate, progression-free survival on first-line treatment, and overall survival.
After a median follow-up of 65.2 months (approximately five and a half years), the study revealed that 63.1% of patients receiving daratumumab had not progressed to active multiple myeloma at the five-year mark, compared to 40.8% of those under active monitoring. For the active monitoring group,the median time to a multiple myeloma diagnosis was 41.5 months (about three and a half years).
The overall response rate was significantly higher in the daratumumab group at 63.4%, compared to 2.0% for those receiving active monitoring. Notably, only 33% of patients in the daratumumab group required treatment for active multiple myeloma, compared to 52% in the active monitoring group.
adverse events requiring treatment occurred in 40.4% of patients receiving daratumumab, compared to 30.1% of those under active monitoring. High blood pressure was the most common moderate-to-severe adverse effect in both groups. A total of 41 patients died during the study: 15 (7.7%) in the daratumumab group and 26 (13%) in the active monitoring group. This difference in mortality was statistically significant.
“This is the first study to show improved outcomes with an agent that is not chemotherapy in patients with a myeloma-related condition. Furthermore,the observed benefit in the overall survival of the daratumumab-treated patients is very encouraging,” Dr. Dimopoulos said.
daratumumab, a biologic therapy derived from living cells, works by targeting proteins on the surface of cancer cells. It directly kills cancer cells and stimulates the patient’s immune system to attack them. The drug is currently approved by the U.S. Food and Drug Management for use in various multiple myeloma treatment regimens.
Dr. Dimopoulos emphasized that these findings specifically apply to patients with smoldering multiple myeloma who have high-risk features. He suggested that future studies should explore the potential benefits of combining daratumumab with other agents to further improve outcomes for these patients.
The study was funded by Janssen Research & Progress,LLC,a sister company of janssen biotech,Inc., the manufacturer of daratumumab. Both companies are subsidiaries of Johnson & Johnson.
A groundbreaking new study has shown that a combination of two oral medications significantly improves survival rates for patients with previously untreated chronic lymphocytic leukemia (CLL). The findings, presented at the 2024 American Society of Hematology (ASH) Annual Meeting, offer a promising new treatment option for this common form of leukemia.
The study, known as AMPLIFY, compared the effectiveness of a fixed-duration regimen of acalabrutinib and venetoclax, with or without the addition of obinutuzumab, to standard multidrug chemotherapy regimens. The results demonstrated that patients receiving the acalabrutinib-venetoclax combination experienced significantly longer periods without their cancer progressing, and they also experienced fewer serious side effects.
“The study met its primary endpoint,demonstrating superior progression-free survival (PFS) for the acalabrutinib-venetoclax combination regimen compared with standard therapy,” said principal investigator Dr. Jennifer R. Brown, director of the CLL Center at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the field of Hematologic Oncology at harvard Medical School in Boston. “Findings were similar when obinutuzumab was added to the two oral agents, and both regimens had manageable safety profiles.”
Dr.Brown highlighted the significance of this new treatment approach. “The acalabrutinib-venetoclax combination offers the first fixed-duration regimen consisting of all oral agents for patients with previously untreated CLL that is expected to be approved in the U.S.,” she explained. “It’s a simple regimen that will be easier for patients to take.”
CLL is the most common type of leukemia in adults in the united states, with approximately 19,000 new cases diagnosed each year. This cancer affects the blood-forming cells in the bone marrow and is more prevalent in individuals aged 65 and older.
Traditional treatment regimens for CLL have included BTK inhibitors like acalabrutinib and ibrutinib, and also BCL2 inhibitors like venetoclax. However, BTK inhibitors often require lifelong use, potentially leading to a buildup of side effects. Venetoclax is frequently combined with obinutuzumab, which is administered intravenously, requiring more frequent clinic visits for patients.
The AMPLIFY trial, conducted in 27 countries, represents a significant advancement in CLL treatment. By offering a fixed-duration, all-oral regimen with improved efficacy and a manageable safety profile, this new combination therapy holds the potential to transform the lives of patients with CLL.
A groundbreaking clinical trial has shown promising results for a new combination therapy in treating chronic lymphocytic leukemia (CLL), a type of cancer affecting white blood cells. The study, known as AMPLIFY, evaluated the effectiveness of two different treatment regimens incorporating acalabrutinib and venetoclax, two drugs already approved for CLL treatment.
the trial, led by Dr.Jennifer R. Brown of the Dana-Farber Cancer Institute and Harvard medical School, involved 867 patients with a median age of 61. Participants were randomly assigned to one of three groups: Group A received acalabrutinib and venetoclax (AV); Group B received acalabrutinib, venetoclax, and obinutuzumab (AVO); and Group C, the control group, received one of two standard chemotherapy regimens chosen by their doctor.
“The addition of obinutuzumab to acalabrutinib and venetoclax improved efficacy but also led to more adverse effects and more COVID deaths,” Dr. Brown said.
The primary goal of the study was to assess progression-free survival (PFS), defined as the time from treatment initiation until the cancer worsened. After a median follow-up of 41 months, both the AV and AVO regimens demonstrated a statistically significant improvement in PFS compared to the standard chemotherapy regimens. Remarkably, 76.8% of patients receiving AV and 83.1% of those receiving AVO remained free of disease progression at the three-year mark, compared to 66.5% of patients in the control group.
While the AVO regimen showed greater efficacy, it also came with a higher incidence of serious adverse events (38.4%) compared to AV (24.7%) and the control group (27.4%). The most common serious side effect across all groups was a low white blood cell count. Notably, 56 patients died from COVID-19 complications during the trial, highlighting the challenges of conducting research during a pandemic.
Dr. Brown emphasized the need for further research to determine which patients benefit most from the addition of obinutuzumab and to understand the factors contributing to relapse in some patients. She also acknowledged that the control group received chemotherapy regimens that are no longer considered standard of care in the U.S., a common challenge in clinical trials due to the evolving nature of medical advancements.
The AMPLIFY trial was funded by AstraZeneca, the manufacturer of acalabrutinib. Dr. Brown will present the study findings on December 9, 2024, at the American Society of Hematology (ASH) annual meeting in San Diego.
A new study offers hope for patients with chronic lymphocytic leukemia (CLL) who have exhausted other treatment options. Epcoritamab, a groundbreaking biologic agent, has shown promising results in early trials, effectively targeting and eliminating cancer cells in patients with relapsed or refractory CLL.
“In heavily pretreated CLL, single-agent epcoritamab had a high overall response rate and a manageable safety profile,” said lead investigator Dr. Alexey Danilov, a professor in the department of hematology & hematopoietic cell transplantation at City of Hope National Medical Center in Duarte, California.
Currently, targeted therapies known as BTK and BCL2 inhibitors are the standard of care for both initial CLL treatment and relapse. However, these treatments often lose effectiveness over time, leaving patients with limited options.
“To date, no treatments have been shown in randomized trials to be effective for patients whose CLL has worsened after treatment with both BTK and BCL2 inhibitors,” Dr. Danilov explained. “There is an unmet need for new treatment options for this group of patients.”
Epcoritamab, administered as a subcutaneous injection, belongs to a class of drugs called bispecific T-cell engagers. It effectively works by linking cancer cells and T cells, the body’s natural immune defenders, enabling a more targeted and potent attack against the cancerous cells. The FDA has already approved epcoritamab for treating two types of lymphoma that have resisted other therapies.
“CLL cells have learned how to evade the body’s immune system,” Dr. Danilov said.”Epcoritamab essentially acts as a bridge, enhancing the ability of immune cells to identify, attack, and destroy the cancer cells.”
The ongoing EPCORE CLL-1 trial is evaluating epcoritamab’s effectiveness in patients with CLL and other blood cancers that have returned after treatment with at least two different therapies, including a BTK inhibitor. The international trial, conducted across 12 countries, aims to enroll a total of 184 patients.
Initial results from the first 40 patients enrolled in the trial, mostly men with a median age of 71.5, are encouraging. Most participants had CLL with aggressive features,such as a TP53 gene mutation or 17p deletion,making their cases particularly challenging to treat.
The primary endpoint for the initial group (EXP cohort) was the overall response rate (ORR), defined as the percentage of patients experiencing complete cancer clearance or at least a 50% reduction in cancer signs. Secondary endpoints included time to cancer progression, overall survival, and minimal residual disease (MRD), which refers to the presence of undetectable cancer cells.
After a median follow-up of 22.8 months, the EXP cohort achieved an ORR of 61%, with 39% of responding patients experiencing complete remission. for all patients in this cohort, the median time to cancer progression was not yet reached.
These early findings suggest that epcoritamab holds significant promise as a new treatment option for patients with relapsed or refractory CLL. Further research and analysis are ongoing to confirm these results and determine the long-term efficacy and safety of this innovative therapy.
A new study has revealed promising results for a novel treatment for chronic lymphocytic leukemia (CLL), a type of cancer affecting white blood cells. The treatment, epcoritamab, demonstrated a remarkable response rate in patients who had previously failed other therapies.
Presented at the 2024 American Society of Hematology (ASH) Annual Meeting, the research focused on two groups of patients: an “expansion cohort” (EXP) and an “optimization cohort” (OPT). In the EXP cohort, which included 23 patients, the overall response rate to epcoritamab was 52%, with 75% of those who underwent minimal residual disease (MRD) testing achieving undetectable levels of cancer cells. “The response rate was very impressive for a single agent, especially considering that most patients had already been treated with both BTK and BCL2 inhibitors without success and had disease features that are challenging to treat,” said Dr. Alexey Danilov,lead author of the study from city of Hope.
While the study showed promising results, Dr. Danilov emphasized the need for further research. “We will need to treat more patients, follow them for a longer period of time, and conduct randomized studies to validate these findings,” he said.”We also want to test epcoritamab in patients with CLL who have had fewer prior therapies. There is reason to believe it might very well be even more effective if used earlier in the disease course,when a patient’s immune system is less compromised.”
The study also highlighted the importance of monitoring for side effects. Low blood counts were common in patients, but Dr.Danilov noted that these were often pre-existing conditions rather than a direct result of the treatment. Cytokine release syndrome (CRS), a potentially serious immune reaction, occurred in 96% of patients, but was mostly mild and manageable.
The OPT cohort, which enrolled patients later in the study, had shorter follow-up time, making it too early to assess the treatment’s effectiveness in this group.However, initial data showed a lower incidence of severe CRS. No patients in either cohort discontinued treatment due to side effects.
This research, funded by GenMab, the co-developer of epcoritamab with AbbVie, offers hope for patients with CLL who have limited treatment options.Further studies will be crucial in confirming these early findings and exploring the full potential of this promising new therapy.
In a separate study presented at the ASH meeting, researchers found a concerning link between exposure to Ground Zero dust and an increased risk of blood cancer in first responders.
The study, which focused on first responders who worked at the World Trade Center site after the 9/11 attacks, revealed that these individuals were three times more likely to have genetic changes associated with an elevated risk of leukemia compared to other first responders or the general public.
What’s particularly alarming is that younger first responders, those under 60, displayed these genetic changes, which are typically rare in individuals under 70. These changes were also unique, differing from those typically observed in aging populations. This suggests that exposure to Ground Zero dust may have triggered specific and potentially more aggressive genetic alterations.
The findings underscore the long-term health consequences faced by first responders who bravely served in the aftermath of the 9/11 attacks. Further research is needed to understand the full extent of these risks and develop strategies for prevention and early detection.
New research reveals a heightened risk of leukemia among first responders who worked at Ground Zero following the September 11th attacks. The study, conducted by researchers at Albert Einstein College of Medicine in the Bronx, New York, found that these responders exhibited distinct genetic changes linked to an increased likelihood of developing blood cancers.
The study, led by Dr. Divij Verma, focused on clonal hematopoiesis (CH), a condition characterized by the overproduction of certain blood cells.While CH typically occurs in individuals over 70, the researchers discovered a significantly higher prevalence among Ground Zero first responders, even those under 60. “Our study has shown not only an increased risk of developing leukemia in Ground Zero-exposed first responders, but also a distinct spectrum of precancerous genetic changes in younger exposed responders,” said Dr.Verma.
“We have also demonstrated that inflammation induced by exposure to toxic dust is the likely mechanism for these genetic changes, and that turning off the IL1RAP gene, in particular, may be a promising strategy to delay or inhibit the development of these genetic changes or prevent progression to leukemia.”
The researchers analyzed blood samples from nearly 1,000 firefighters and emergency medical personnel who were present at Ground Zero.They compared these samples to those from firefighters who hadn’t been at the site and individuals from the general population. The results showed that 14% of the Ground Zero responders had CH, compared to 7% in the other groups.
Furthermore, the study identified specific gene mutations, such as APC, KMT2D, ATM, PIK3CA, CREBBP, BRCA2, ERBB4, and ARID1A, that were more prevalent in younger Ground Zero responders. These mutations have not been previously observed in CH studies.
“Notably,in the firefighters and other first responders who had no Ground Zero exposure,the risk of having CH was the same as for people who were not first responders and had not been to the site,” Dr. Verma noted.
The study also found that among Ground Zero responders with CH, 3.7% developed leukemia, compared to 0.6% in the non-exposed groups. These findings underscore the long-term health consequences faced by first responders who bravely served in the aftermath of the 9/11 attacks.
Dr. Verma and his team are continuing their research to better understand the specific toxic components of the Ground Zero dust and their impact on human health. They are also investigating whether these effects are unique to Ground Zero exposure or if they are similar to those seen in individuals exposed to other environmental hazards, such as wildfires and burn pits.
The researchers are actively contacting all ground Zero responders with CH to provide them with early health monitoring and treatment options if necessary.This study serves as a crucial reminder of the ongoing health challenges faced by first responders and the importance of continued research and support for these individuals.
New research presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition reveals promising insights into the fight against inflammation-driven cancers. A study conducted by Dr. Divij Verma and his team at Albert Einstein College of Medicine found that deleting the gene for IL1RAP, a protein involved in inflammatory signaling, effectively halted precancerous changes in mice.
“IL1RAP is a potentially vital target for reducing inflammation and combating inflammation-driven malignancies,” Dr. Verma explained. “Targeting IL1RAP holds significant potential for treating these types of cancers.”
While these findings are encouraging, Dr. Verma emphasized that further research is needed to determine if this strategy will be effective in humans.
This study was funded by grants from the U.S.Centers for disease Control and Prevention and the National institutes of Health.
In a separate study,researchers shed light on the disparities in access to life-saving stem cell transplants for patients with acute myeloid leukemia (AML).
A prospective, multi-center study led by Dr. Natalie Wuliji, an assistant professor at Fred hutchinson Cancer Center in Seattle, found that patients living in disadvantaged neighborhoods faced significant barriers to receiving allogeneic hematopoietic cell transplants (HCT), also known as stem cell transplants.
“Our results could set the stage to help identify targeted interventions to improve access to HCT for patients with AML who face socioeconomic barriers,” Dr. Wuliji said.
The study, which followed 692 patients with AML, revealed that individuals residing in areas with lower education levels, higher poverty rates, and greater reliance on federal assistance programs were less likely to receive HCT and more likely to die without it.
“We found that social and economic barriers have a greater impact on the ability to receive a transplant or on the risk of death before transplant than on outcomes after the transplant,” Dr. Wuliji explained. “These findings suggest that access to allo-HCT may help level the playing field for AML patients across socioeconomic backgrounds, though further studies are needed to confirm this.”
Dr. Wuliji highlighted the challenges associated with HCT, including its high cost, limited availability at specialized centers, and the need for lengthy hospital stays. These factors disproportionately affect patients and families with limited resources, difficulty taking time off work, or inadequate health insurance coverage.
Both studies underscore the critical need for continued research and innovative approaches to address health disparities and improve outcomes for all patients.
A new study has shed light on the stark disparities in access to life-saving hematopoietic cell transplantation (HCT) for adults with acute myeloid leukemia (AML) in the United States. The research, conducted by a team at Fred Hutchinson Cancer center and published in the journal Blood, revealed a troubling link between socioeconomic factors and both the likelihood of receiving HCT and the risk of mortality.
The study analyzed data from over 1,000 adult AML patients treated at 13 medical centers across the country. Researchers tracked patient outcomes for a median of 4.5 years following their diagnosis, meticulously examining the impact of social determinants of health (SDOH) on their access to HCT and survival rates.
“Our findings underscore the profound influence of socioeconomic factors on health equity in AML treatment,” said Dr.Natalie wuliji, lead author of the study. ”Patients living in neighborhoods characterized by lower education levels, higher poverty rates, and greater reliance on social safety net programs faced significantly higher barriers to receiving HCT and experienced poorer outcomes.”
The study found that patients residing in zip codes with a higher percentage of residents lacking a high school diploma, receiving Supplemental Security Income (SSI), or relying on Supplemental Nutrition Assistance Program (SNAP) benefits were significantly less likely to undergo HCT. “Such as, the risk of dying without receiving HCT increased by 24% as the proportion of zip-code residents with less than a high school education increased by 10%,” Dr. Wuliji explained.
Furthermore, the study revealed a concerning racial disparity in access to HCT. While Asian patients had a 34% higher likelihood of receiving the treatment compared to white patients, Black patients faced an 18% reduced likelihood. Dr. Wuliji cautioned that the small percentage of non-white patients in the study limited definitive conclusions about the impact of race, but the findings highlight the need for further investigation.
The researchers also observed a correlation between median household income and HCT access. A $25,000 increase in median income within a zip code was associated with a 5% increase in the likelihood of receiving HCT.
Even among patients who did receive HCT, those living in socioeconomically disadvantaged areas faced a higher risk of death following the procedure. “This suggests that SDOH may not only impact access to care but also influence outcomes after treatment,” Dr. Wuliji noted.
The study’s findings underscore the urgent need to address the systemic inequities that contribute to disparities in AML care. Dr. Wuliji and her team are actively working on initiatives to increase participation of underrepresented groups in clinical trials and develop culturally sensitive patient education materials.
Future research will focus on exploring innovative strategies to improve access to HCT for patients living in underserved communities. “We believe that by addressing the social and economic barriers that hinder access to quality care, we can work towards achieving health equity for all AML patients,” Dr. Wuliji concluded.
This study was funded by grants from the Patient-Centered Outcomes Research Institute, the American Cancer Society, and the American Society of Hematology.
San Diego, CA – The American Society of Hematology (ASH) announced today the groundbreaking results of a new study presented at the 65th ASH Annual Meeting and Exposition. The research, which focused on [insert specific area of hematology research], offers promising advancements in the understanding and treatment of [Mention specific blood disorder or condition].
“These findings represent a significant step forward in our fight against [Mention specific blood disorder or condition],” said [Lead researcher’s name and title], lead author of the study. “[Quote from lead researcher about the significance of the findings].”
The study, conducted by a team of researchers from [List institutions involved], involved [ Briefly describe the study methodology, e.g., a clinical trial with X number of participants]. Key findings include [Summarize 2-3 key findings of the study].
“This research has the potential to [Explain the potential impact of the findings on patient care, treatment options, or future research].We are excited to see how these findings will translate into tangible benefits for patients,” added [Quote from another researcher or expert involved in the study, if available].
The American Society of Hematology (ASH) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more details about ASH, visit hematology.org.
The Blood journals are the premier source for basic, translational, and clinical hematological research. They publish more peer-reviewed hematology research than any other academic journals worldwide. For more information, visit https://ashpublications.org/journals.
SOURCE: American Society of Hematology
Reaching a vast and influential audience is crucial for any news story to make an impact. That’s precisely what PR newswire delivers, boasting an impressive network that spans the globe.
With over 440,000 newsrooms and influencers in its reach, PR Newswire ensures your message resonates with key players in the media landscape. This extensive network includes over 9,000 digital media outlets, guaranteeing widespread coverage across diverse platforms.
“We connect you with the right audiences,” the company emphasizes, highlighting its commitment to targeted distribution. This dedication is further underscored by a network of over 270,000 journalists who have opted in to receive news releases through PR Newswire.
For organizations seeking to amplify their message and reach a global audience, PR Newswire’s expansive network offers a powerful platform for success.
Your provided text is an excellent starting point for generating a compelling press release about important hematology research. It effectively summarizes key findings and incorporates quotes from researchers. Here are some suggestions to refine it further:
**1. Stronger Hook:** Start with a captivating opening sentence that grabs attention and highlights the significance of the research. For example:
* “A groundbreaking finding in the field of hematology offers new hope for patients battling [mention specific blood disorder].”
* “Scientists have made a significant breakthrough in unlocking the secrets of [mention specific blood disorder],paving the way for potential new therapies.”
**2. Specificity:** While you mention “IL1RAP,” “inflammatory-driven malignancies,” and ”hematopoietic cell transplantation,” consider providing more context:
* What specific type of precancerous changes were halted?
* What types of inflammatory-driven malignancies are targeted?
* What are the specific barriers to transplantation faced by disadvantaged patients?
**3.Impactful Language:**
* Use strong verbs and evocative language to emphasize the importance of the findings.
**4. Call to Action:** Conclude with a call to action.For example you could mention:
* Next steps for the research.
* where patients can learn more about clinical trials.
* How the public can support hematology research.
**5. Quote Variety:** include quotes from diverse perspectives, such as:
* Patients who may benefit from these findings.
* Medical professionals outside of the research team who can comment on the broader implications.
**Example Improved Opening Paragraph:**
“A monumental discovery by researchers at [Institution name] could revolutionize the treatment of [Specific blood disorder].A new study presented at the 65th ASH annual meeting and Exposition has revealed that blocking the activity of a protein called IL1RAP effectively halted precancerous changes in mice, offering promising potential for preventing [Mention specific type of cancer] in humans. “
**Remember:** This is a press release, so keep it concise and focused on the most newsworthy aspects of the research. Use clear, accessible language that can be understood by a general audience.
